Skip to content

Total Cerebral Protection With Embolic Protection Devices Thoracic Aortic Stenting

Total Cerebral Protection With Embolic Protection Devices in Thoracic Aortic Stenting

Status
Suspended
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04062539
Enrollment
30
Registered
2019-08-20
Start date
2018-10-04
Completion date
2021-11-30
Last updated
2019-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Silent Cerebral Infarct, Stroke

Keywords

stroke, cerebral embolic protection device

Brief summary

Stroke and silent cerebral infarction are a real risk with thoracic enodvascular aortic repair (TEVAR). The investigator propose to prospectively observational study with enrolment of all patients undergoing TEVAR for thoracic and thoracoabdominal conditions including aneurysmal degeneration, Type B dissection and acute aortic syndromes over a 24 month period, equating to a minimum of 20-30 patients per year. Patients undergoing juxtra-renal and infra-renal aortic stenting will form a control group.

Detailed description

TEVAR involves the insertion of a stent into the thoracic aorta to re-line it and prevent life-threatening haemorrhage from rupture, and ultimately death. The stent is inserted through a small cut in the femoral artery in the groin that is able to track to the desired location in the thoracic aorta over wires. The thoracic aorta and the branches it provides to supply the brain are diseased with atherosclerotic plaques and thrombus. The manipulation of wires and stents over these diseased locations can lead to small fragments breaking off and travelling to the brain to block the blood supply to areas of the brain (cerebral embolisation). Cerebral embolic protection devices (CEPDs) consist of filters that can be placed into the branches of the thoracic aorta that supply the brain(supra-aortic branches) before TEVAR and can capture and remove solid debris, preventing it from reaching the brain.

Interventions

DEVICESentinel and Spider

Dual filter and single filter

Sponsors

St Mary's Hospital, London
CollaboratorOTHER
Imperial College London
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* All patients requiring TEVAR as decided upon by a multidisciplinary meeting

Exclusion criteria

* Contraindication to MRI scanning * Unable to give consent

Design outcomes

Primary

MeasureTime frameDescription
Incidence of brain injury assessed by Magnetic resonance imaging (MRI) testPre-operative and post-operative up to 6 monthsMagnetic resonance imaging (MRI) of the brain is a safe and painless test that uses a magnetic field and radio waves to produce detailed images of the brain.

Secondary

MeasureTime frameDescription
Incidence of embolic eventIntra-operativeTranscranial doppler monitoring of embolic events
Changes in neurocognition functionPre-operative and post-operative up until 6 monthsNeurocognitive tests to assess the changes in neurocognition function

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026